Tobin Schilke - 01 Mar 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Mar 2023
Net transactions value
-$107,234
Form type
4
Filing time
02 Mar 2023, 20:25:57 UTC
Previous filing
16 Feb 2023
Next filing
17 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale $107,234 -3,201 -6.1% $33.50 49,390 01 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.